Pre-Meeting Workshop: The Delicate Art of Uncovering Suicidal Ideation and Intent: The Chronological Assessment of Suicide Events (CASE Approach)

The 2013 CPNP Annual Meeting Pre-Meeting Workshop is focused on one of the most challenging issues of our day-suicide. On Sunday, April 21, we kick off with a half-day workshop focused on developing state of the art skills necessary to tackle some of the most difficult and critical tasks in the assessment of suicide risk. In this training, Dr. Shawn Shea describes an innovative interviewing strategy for eliciting suicidal ideation, behaviors, and intent – the Chronological Assessment of Suicide Events (the CASE Approach).

The workshop starts with a focus on the seven practical validity techniques which form the cornerstones for effectively eliciting suicidal ideation: normalization, shame attenuation, the behavioral incident, gentle assumption, denial of the specific, the catch-all question, and symptom amplification. Dr. Shea demonstrates how these interviewing techniques can provide powerful gateways for uncovering the types of sensitive and taboo topics that may lead to suicidal thoughts including: physical abuse, drug abuse, antisocial behavior, and incest.

The workshop concludes with numerous demonstrations of how these validity techniques can be woven into a specific strategy for specifically uncovering suicidal ideation, behaviors, and intent using the CASE Approach. All interviewing techniques will be clearly demonstrated through active learning and the use of videotape examples from actual patient interviews.

View a Counseling Points Newsletter on the Medication Interest Model

Read more about this session.

The Medication Interest Model (MIM): Innovative Interviewing Techniques for Improving Medication Adherence

Monday, April 22, 2013, 9:00-10:30 AM

Shawn Shea, MD, looks at the methods by which clinicians address this crucial topic as they build their alliances with their patients. An internationally acclaimed workshop leader and educational innovator in the fields of suicide prevention, resiliency, clinical interviewing, and improving medication adherence, Dr. Shea brings to life the practical interviewing techniques of the Medication Interest Model (MIM). The MIM explores how a clinician’s language is often the determining factor in whether or not the clinician is viewed as an opponent “pushing meds” or as an ally helping to provide useful information on both the benefits and side-effects of medications. Specific interviewing techniques, choice of words, and strategies are described in detail in a fast-paced, lively and compelling style. Read more about this session.

Trends in Synthetic Drugs of Abuse

Synthetic drugs are increasingly abused and are easily available at in retail stores and online. In many cases there are minimal restrictions on purchase, and owing to their legal status are often assumed to be safe. Newer synthetic drugs are responsible for adverse events, ER visits and calls to poison control centers. These drugs are difficult to legislate, as restrictions often result in manufacturers making minimal alterations that result in new, legal versions. Omar Manejwala, MD, MBA, FAPA, will discuss the pharmacological aspects of newer synthetic drugs of abuse, their clinical effects, and the role that pharmacists can play in synthetic drug use prevention and early intervention, including advocacy for policy change. Read more about this session.

Rewriting the Psychiatric Bible: The DSM-5 and its Implications

In May 2013, the American Psychiatric Association will release the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, DSM-5. The DSM-5 is so critical to the contemporary practice of psychiatry that it is often called the ‘psychiatric bible.’ While alternative diagnostic manuals exist, the DSM-5 is the clear standard, in both domestic and international psychiatry. In order to prepare for the release of DSM-5, practitioners need to review the history of the DSM, the rationale behind this revision, the categorical and organizational changes in DSM-5, and how DSM-5 will alter clinical practice. We will review these topics together, considering the strengths and limitations of DSM-5, alternative diagnostic systems, and how each version of the DSM corresponds to its historical moment. Read more about this session.

Transforming 300 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Disease

Wednesday, April 24, 2013, 10:00-11:00 AM

There is an urgent need to translate genome-era discoveries into clinical utility, but the difficulties in making bench-to-bedside translations have been well described. Large funding initiatives have led to the systematic measurements of many relevant aspects of biology, from transcription and translation to the workings of pharmacology. But very little of this data is actually ever used beyond the handful of papers that introduce these data to the world.

The nascent field of translational bioinformatics may bridge these opportunities. Dr. Butte’s lab at Stanford builds and applies tools that convert more than 300 billion points of molecular, clinical, and epidemiological data -- measured by researchers and clinicians over the past decade -- into diagnostics, therapeutics, and new insights into disease. Dr. Butte, a bioinformatician and pediatric endocrinologist, will highlight his lab’s work on using publicly-available molecular measurements to find new uses for drugs including drug repositioning for inflammatory bowel disease and discovering new treatable inflammatory mechanisms of disease in type 2 diabetes, and how patients presenting with whole genome sequences can be evaluated. As the new Principal Investigator of ImmPort, the long-term, sustainable data warehouse of immunological data generated by NIAID-funded investigators, Dr. Butte will highlight how molecular and clinical trials data can be shared and reused to drive scientific discovery.

View a 14 minute clip of Dr. Butte at TEDMED 2012

Read more about this session.